This site is intended for Healthcare Professionals only.

Pandemic delivery service to continue in local outbreak areas

Date:

Share post:

The Covid-19 pandemic pharmacy prescription delivery service will remain in force from September 1 to 7 for shielded patients who reside in Leicester City lockdown area and Blackburn with Darwen.

The latest change to the service requirements was announced in a letter published by NHS England and NHS Improvement last week. Further announcements may be made depending on the government advice and decision.

The pharmacy contractors located in the local outbreak areas will receive the essential service payment in September 2020.

If a contractor, excluding distance selling pharmacies, located anywhere in England, is asked to deliver a prescription to a shielded patient living in one of the local outbreak areas, the pharmacies can continue with the service until September 7, under the terms of the advanced service and a claim for payment can be made by October 5 via the Manage Your Service (MYS) platform.

A community pharmacy home delivery service during the Covid-19 outbreak was commissioned throughout England from community pharmacies (and a similar service from dispensing doctors) to ensure delivery of medicines to eligible patients who should not be present in the pharmacy.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

40% of Brits ready to embrace pharmacy delivery service

Same-day delivery and real-time tracking could be key to winning over consumers skeptical about pharmacy delivery service A survey...

PDA opposes DiCE guidance on online prescribing for GLP-1 agonist

PDA has withheld its endorsement of the DiCE guidance due to concerns over patient safety The Pharmacist's Defence Association...

Locum Pharmacist acquires 30-hour Moorside Pharmacy

The new owner plans to run Moorside Pharmacy on a hands-on basis and introduce additional services for the...

Breakthrough: Cabotegravir shows 88% reduction in HIV-1 incidence

Recommended by NICE and approved by the MHRA, Cabotegravir 600 mg long-acting injection is the first injectable treatment...